WAVE Life Sciences Ltd (FRA:1U5)
€ 12.8 -0.1 (-0.78%) Market Cap: 1.89 Bil Enterprise Value: 1.62 Bil PE Ratio: 0 PB Ratio: 13.52 GF Score: 41/100

WAVE Life Sciences Ltd Business Update Transcript

Dec 13, 2022 / 01:30PM GMT
Release Date Price: €3.98 (+11.39%)
Operator

Ladies and gentlemen, thank you for standing by, and welcome to the Wave Life Sciences business update. (Operator Instructions)

I would now like to turn the call over to your host, (inaudible), you may begin.

Unidentified Company Representative

Thank you, operator. Good morning, and thank you for joining us today. I will be covering for Kate Rausch, while she's on maternity leave. This morning, Wade issued a news release announcing a strategic collaboration between Wave and GSK, focused on discovery and development of oligonucleotide therapeutics. The slide presentation to accompany this webcast is available at the Investors section of our website at www.Wavelifesciences.com. A replay of this call will also be available on the website following the call.

Joining me on the call today with prepared remarks is Dr. Paul Bolno, Wave's President and Chief Executive Officer; Chris Francis, Waveâs SVP of Corporate Development, is also on the call and will be available for questions.

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot